Oligofluorinated Vascular Graft Surfaces for Lower Thrombogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic vascular grafts face challenges in small vessel replacement due to issues such as thrombosis, intimal hyperplasia, and immunogenicity, with autologous and allografts having limitations like availability and degeneration, while synthetic grafts often fail due to inappropriate diameter and structural defects.
Innovation Solution
Incorporating an oligofluorinated additive with base polymers like polyethylene terephthalate, polytetrafluoroethylene, or polyurethane into the inner surface of vascular grafts to reduce thrombogenicity, using additives described by specific molecular structures to enhance biocompatibility and mechanical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If synthetic grafts are used for small vessel replacement, then structural strength and durability are improved, but thrombosis and intimal hyperplasia occur due to poor biocompatibility
Solution Approach 1:
The patent applies local quality by treating only the inner surface of the graft with oligofluorinated compounds while maintaining the bulk properties of the synthetic polymer. This localized modification reduces thrombogenicity at the blood-contacting surface without compromising the overall structural strength and durability of the graft material.
Solution Approach 2:
The patent changes the chemical parameters of the graft surface by incorporating oligofluorinated additives with specific molecular structures (containing CF3 and CF2 groups). This chemical parameter modification alters the surface properties to reduce thrombogenicity while maintaining the mechanical properties of the base polymer.
2Object-affected harmful factors
If autologous veins are used for small vessel replacement, then biocompatibility and patency rates are improved, but availability is limited due to donor site complications
Solution Approach 1:
The patent uses oligofluorinated compounds as an intermediary substance that mediates between the synthetic graft material and the biological environment. This intermediary layer improves biocompatibility by reducing thrombogenicity and intimalhyperplasia, making synthetic grafts more suitable for small vessel replacement without requiring autologous tissue.
3Adaptability or versatility
If allografts or heterografts are used for vessel replacement, then availability is improved, but immunogenicity and degeneration occur over time
Solution Approach 1:
The patent creates a composite material system combining a synthetic polymer base (such as polyethylene terephthalate, polytetrafluoroethylene, or polyurethane) with oligofluorinated surface modifiers. This composite approach provides the availability of synthetic materials while the fluorinated surface layer improves long-term durability by reducing immunogenicity and preventing degeneration.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
Disclosed are vascular grafts having a surface modified to reduce the risk of thrombi formation post implantation into a subject. The vascular graft can include a tubular structure comprising a base polymer admixed with an oligofluorinated additive.